VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
AMGNAmgen Inc.
$337.60$182.2B
Research
OverviewAnalysisShould I Buy?
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksAMGNP/E History

AMGN logoAmgen Inc. (AMGN) P/E Ratio History

Fairly Valued

Trading at 23.7x, near 5Y avg of 25.8x · 60th percentile · In line with own history · Data 1990–2026

Current P/E (TTM)
23.7x
-8% vs 5Y avg
5Y Avg P/E
25.8x
Median 23.0x
5Y Percentile
60th
Mid-range
PEG Ratio
8.07
Premium to growth
5-Year P/E Range
23.7x
Min15.0xMedian23.0xMax53.8x
TTM EPS$14.34
Price$337.60
Earnings Yield4.21%
EPS Growth (1Y)88.2%
EPS Growth (5Y)2.9%

Loading P/E history...

P/E Ratio Analysis

As of June 21, 2026, Amgen Inc. (AMGN) trades at a price-to-earnings ratio of 23.7x, with a stock price of $337.60 and trailing twelve-month earnings per share of $14.34.

The current P/E is roughly in line with its 5-year average of 25.8x. Over the past five years, AMGN's P/E has ranged from a low of 15.0x to a high of 53.8x, placing the current valuation at the 60th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.1x, AMGN is roughly in line with its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.

The PEG ratio of 8.07 (P/E divided by 88% EPS growth) suggests the stock may be expensive relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.

Relative to the broader market, AMGN trades roughly in line with the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our AMGN DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

AMGN Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
23.7vs22.1
+7%
In Line with Sector
vs. S&P 500
23.7vs24.4
-3%
In Line with Market
PEG Analysis
8.07
P/E ÷ EPS Growth
PEG > 2 = Expensive
Based on 88% EPS growth (1Y)

AMGN P/E vs Peers

Specialty and biologics-focused pharma peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
GILD logoGILDGilead Sciences, Inc.
$154B18.30.14Best+1684%Best
BIIB logoBIIBBiogen Inc.
$29B22.3--21%
REGN logoREGNRegeneron Pharmaceuticals, Inc.
$63B14.7Lowest2.32+8%
VRTX logoVRTXVertex Pharmaceuticals Incorporated
$115B29.53.56+837%
BMY logoBMYBristol-Myers Squibb Company
$110B15.7-+178%
LLY logoLLYEli Lilly and Company
$1.0T47.81.66+96%
ABBV logoABBVAbbVie Inc.
$383B91.4--1%
MRK logoMRKMerck & Co., Inc.
$281B15.60.74+8%
PFE logoPFEPfizer Inc.
$143B18.5--4%
JNJ logoJNJJohnson & Johnson
$550B39.4--58%

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

AMGN Historical P/E Data (1990–2026)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2026 Q1-$351.85$14.3724.5x-14%
FY2025 Q4Dec 31 2025$327.31$14.2323.0x-19%
FY2025 Q3-$282.20$12.9421.8x-23%
FY2025 Q2Jun 30 2025$279.21$12.2322.8x-20%
FY2025 Q1Mar 31 2025$311.55$10.9628.4x+0%
FY2024 Q4-$260.64$7.5534.5x+22%
FY2024 Q3Sep 30 2024$322.21$7.8141.3x+45%
FY2024 Q2Jun 30 2024$312.45$5.8153.8x+89%
FY2024 Q1Mar 31 2024$284.32$7.0040.6x+43%
FY2023 Q4Dec 31 2023$288.02$12.4923.1x-19%
FY2023 Q3Sep 30 2023$268.76$14.0719.1x-33%
FY2023 Q2Jun 30 2023$222.02$14.8315.0x-47%
FY2023 Q1Mar 31 2023$241.75$14.7116.4x-42%
FY2022 Q4Dec 31 2022$262.64$12.1121.7x-24%
FY2022 Q3Sep 30 2022$225.40$12.4718.1x-36%
FY2022 Q2-$243.30$11.8020.6x-27%
FY2022 Q1-$241.82$10.1623.8x-16%
FY2021 Q4Dec 31 2021$224.97$10.3121.8x-23%
FY2021 Q3-$212.65$9.7121.9x-23%
FY2021 Q2Jun 30 2021$243.75$9.8324.8x-13%
FY2021 Q1Mar 31 2021$248.81$12.0720.6x-27%
FY2020 Q4-$229.92$12.3118.7x-34%
FY2020 Q3Sep 30 2020$254.16$12.4020.5x-28%
FY2020 Q2-$235.86$12.2419.3x-32%
FY2020 Q1-$202.73$12.7615.9x-44%
FY2019 Q4-$241.07$12.8718.7x-34%
FY2019 Q3Sep 30 2019$193.51$13.0314.9x-48%
FY2019 Q2Jun 30 2019$184.28$12.6214.6x-49%
FY2019 Q1Mar 31 2019$189.98$12.5315.2x-47%
FY2018 Q4Dec 31 2018$194.67$12.6015.4x-46%
FY2018 Q3Sep 30 2018$207.29$3.7056.0x+97%
FY2018 Q2Jun 30 2018$184.59$3.6051.3x+81%
FY2018 Q1Mar 31 2018$170.48$3.0356.3x+98%
FY2017 Q4Dec 31 2017$173.90$2.5767.7x+138%
FY2017 Q3Sep 30 2017$186.45$11.0516.9x-41%
FY2017 Q2Jun 30 2017$172.23$10.9715.7x-45%
FY2017 Q1Mar 31 2017$164.07$10.5315.6x-45%
FY2016 Q4Dec 31 2016$146.21$10.2414.3x-50%
FY2016 Q3Sep 30 2016$166.81$10.0216.6x-41%
FY2016 Q2-$152.15$9.7815.6x-45%
FY2016 Q1-$149.93$9.4615.8x-44%
FY2015 Q4-$162.33$9.0717.9x-37%
FY2015 Q3Sep 30 2015$138.32$8.3816.5x-42%
FY2015 Q2-$153.52$7.5520.3x-28%
FY2015 Q1-$159.85$7.4121.6x-24%
FY2014 Q4Dec 31 2014$159.29$6.7023.8x-16%
FY2014 Q3-$140.46$6.3522.1x-22%
FY2014 Q2Jun 30 2014$118.37$6.5318.1x-36%
FY2014 Q1Mar 31 2014$123.34$6.1720.0x-30%
FY2013 Q4-$114.08$6.6517.2x-40%
FY2013 Q3Sep 30 2013$111.93$6.3317.7x-38%
FY2013 Q2Jun 30 2013$98.66$5.9516.6x-42%
FY2013 Q1Mar 31 2013$102.51$5.9117.3x-39%
FY2012 Q4Dec 31 2012$86.20$5.5115.6x-45%
FY2012 Q3Sep 30 2012$84.29$5.6714.9x-48%
FY2012 Q2Jun 30 2012$72.91$4.7615.3x-46%
FY2012 Q1Mar 31 2012$67.97$4.4015.4x-46%
FY2011 Q4Dec 31 2011$64.21$4.1215.6x-45%
FY2011 Q3Sep 30 2011$54.96$4.0413.6x-52%
FY2011 Q2-$58.35$4.8212.1x-57%
FY2011 Q1-$53.45$4.8211.1x-61%
FY2010 Q4Dec 31 2010$54.90$4.8011.4x-60%
FY2010 Q3-$55.11$4.6511.9x-58%
FY2010 Q2Jun 30 2010$52.60$4.7311.1x-61%
FY2010 Q1Mar 31 2010$59.84$4.7312.7x-55%
FY2009 Q4-$56.57$4.5312.5x-56%
FY2009 Q3Sep 30 2009$60.23$4.5213.3x-53%
FY2009 Q2-$52.94$4.2512.5x-56%
FY2009 Q1-$49.52$3.8712.8x-55%
FY2008 Q4Dec 31 2008$57.75$3.9314.7x-48%
FY2008 Q3-$59.27$3.7615.8x-44%
FY2008 Q2Jun 30 2008$47.16$2.8516.5x-42%
FY2008 Q1Mar 31 2008$41.78$2.8814.5x-49%
FY2007 Q4Dec 31 2007$46.44$2.7816.7x-41%
FY2007 Q3Sep 30 2007$56.57$2.7320.7x-27%
FY2007 Q2Jun 30 2007$55.29$3.4915.8x-44%
FY2007 Q1Mar 31 2007$55.88$2.6021.5x-24%
FY2006 Q4Dec 31 2006$68.31$2.4827.5x-3%
FY2006 Q3Sep 30 2006$71.53$2.4529.2x+3%
FY2006 Q2Jun 30 2006$65.23$2.2828.6x+1%
FY2006 Q1Mar 31 2006$72.75$3.0923.5x-17%
FY2005 Q4Dec 31 2005$78.86$2.9426.8x-6%
FY2005 Q3Sep 30 2005$79.67$2.7928.6x+1%
FY2005 Q2-$60.46$2.2027.5x-3%
FY2005 Q1-$58.21$1.9529.9x+5%
FY2004 Q4Dec 31 2004$64.15$1.8035.6x+26%
FY2004 Q3-$56.81$1.6833.8x+19%
FY2004 Q2Jun 30 2004$54.57$1.9627.8x-2%
FY2004 Q1Mar 31 2004$58.15$1.8431.6x+11%
FY2003 Q4Dec 31 2003$61.79$1.6936.6x+29%
FY2003 Q3-$64.52$1.6239.8x+40%
FY2002 Q2Jun 30 2002$41.88$1.1536.4x+28%
FY2002 Q1Mar 31 2002$59.68$1.0755.8x+96%
FY2001 Q4Dec 31 2001$56.44$1.0354.8x+93%
FY2001 Q3Sep 30 2001$58.77$1.0754.9x+93%
FY2001 Q2Jun 30 2001$60.68$1.1055.2x+94%
FY2001 Q1Mar 31 2001$60.19$1.0855.7x+96%
FY2000 Q4Dec 31 2000$63.94$1.0560.9x+114%
FY2000 Q3Sep 30 2000$69.83$1.1262.3x+120%
FY2000 Q2Jun 30 2000$70.25$1.0765.7x+131%
FY2000 Q1Mar 31 2000$61.38$1.0459.0x+108%
FY1999 Q4Dec 31 1999$60.06$1.0258.9x+107%
FY1999 Q3-$40.75$0.9841.6x+46%
FY1999 Q2Jun 30 1999$30.44$0.9133.5x+18%
FY1999 Q1Mar 31 1999$37.44$0.8743.0x+52%
FY1998 Q4-$26.14$0.8231.9x+12%
FY1998 Q3Sep 30 1998$18.89$0.7724.5x-14%
FY1998 Q2-$16.34$0.6425.5x-10%
FY1998 Q1-$15.22$0.6125.0x-12%
FY1997 Q4Dec 31 1997$13.53$0.6022.6x-21%
FY1997 Q3-$11.98$0.6020.0x-30%
FY1997 Q2Jun 30 1997$14.53$0.6821.4x-25%
FY1997 Q1Mar 31 1997$13.97$0.6621.2x-25%
FY1996 Q4-$13.59$0.6221.9x-23%
FY1996 Q3Sep 30 1996$15.78$0.5827.2x-4%
FY1996 Q2Jun 30 1996$13.50$0.5524.5x-14%
FY1996 Q1Mar 31 1996$14.53$0.5227.9x-2%
FY1995 Q4Dec 31 1995$14.84$0.4930.3x+7%
FY1995 Q3Sep 30 1995$12.47$0.3634.2x+21%
FY1995 Q2Jun 30 1995$10.05$0.3429.2x+3%
FY1995 Q1Mar 31 1995$8.42$0.3126.8x-6%
FY1994 Q4Dec 31 1994$7.38$0.3024.2x-15%
FY1994 Q3Sep 30 1994$6.66$0.3817.5x-38%
FY1994 Q2-$5.36$0.3614.8x-48%
FY1994 Q1-$4.78$0.3513.6x-52%
FY1993 Q4Dec 31 1993$6.19$0.3418.2x-36%
FY1993 Q3-$4.83$0.3812.7x-55%
FY1993 Q2Jun 30 1993$4.56$0.3712.3x-57%
FY1993 Q1Mar 31 1993$4.72$0.3513.5x-53%
FY1992 Q4-$8.83$0.3326.8x-6%
FY1992 Q3Sep 30 1992$7.84$0.2729.4x+3%
FY1992 Q2-$7.61$0.2432.1x+13%
FY1992 Q1-$7.81$0.2038.1x+34%
FY1991 Q4-$9.47$0.1282.3x+190%
FY1991 Q3Sep 30 1991$6.91$0.0888.6x+212%
FY1991 Q1Mar 31 1991$5.47$0.05114.0x+301%
FY1990 Q4Dec 31 1990$2.59$0.02148.0x+421%
FY1990 Q3Sep 30 1990$1.86$0.0632.3x+14%
FY1990 Q2Jun 30 1990$1.62$0.0534.1x+20%
FY1990 Q1Mar 31 1990$1.29$0.0434.4x+21%

Average P/E for displayed period: 28.4x

Export Data
Consensus-Based Analysis Tools

Full Stock Analysis

Deep dive into AMGN consensus models and risk factors.

View Analysis

Should I Buy AMGN?

Wall Street verdict, signals, and target summaries.

See Verdict

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

36+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

AMGN — Frequently Asked Questions

Quick answers to the most common questions about buying AMGN stock.

What is AMGN's P/E ratio?

Amgen Inc. (AMGN) trailing twelve-month P/E ratio is 23.7x, based on TTM diluted EPS of $14.34. The 5-year average P/E is 25.8x and the historical range spans 15.0x to 53.8x.

Is AMGN stock overvalued or undervalued?

AMGN trades at 23.7x P/E, near its 5-year average of 25.8x. The 60th percentile ranking within the 15.0x–53.8x historical range places valuation within normal bounds.

Is AMGN stock expensive?

AMGN is fairly valued relative to its own history. The current P/E of 23.7x is near the 5-year average of 25.8x (60th percentile of historical range).

What is AMGN's historical P/E range?

Over the past 5 years, AMGN's P/E ratio has ranged from 15.0x to 53.8x, with a median of 23.0x and an average of 25.8x. The current P/E of 23.7x places the stock at the 60th percentile of this range. Full historical data spans 1990–2026.

How does AMGN's P/E compare to the S&P 500?

AMGN trades at 23.7x P/E versus the S&P 500 median of 24.4x. The 3% discount to the market suggests lower growth expectations or perceived higher risk.

How does AMGN's valuation compare to Healthcare peers?

Amgen Inc. P/E of 23.7x compares to the Healthcare sector median of 22.1x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is AMGN's PEG ratio?

AMGN PEG ratio is 8.07, based on a P/E of 23.7x and EPS growth of 88.2%. A PEG above 2.0 indicates a premium valuation relative to earnings growth — typically considered expensive.

What is AMGN's earnings yield?

AMGN earnings yield is 4.21%, the inverse of its 23.7x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

AMGN P/E Ratio History (1990–2026)

Quarterly valuation multiple from closing price and trailing EPS

Current24.5x
Period Avg25.8x
Range15.0x - 53.8x
Change-1%
20 quartersJun 30, 2021 - Mar 31, 2026